Loading...
•
Mar 31, 2021
MacroGenics Q1 2021 Earnings Report
MacroGenics' financial results for Q1 2021 were reported, and corporate progress was updated.
Key Takeaways
MacroGenics reported total revenue of $16.9 million for the quarter ended March 31, 2021, including $0.9 million net sales of MARGENZA. Net loss was $51.3 million. Cash, cash equivalents and marketable securities were $343.2 million as of March 31, 2021.
MARGENZA™ was launched in mid-March.
MGC018 initial Phase 1 clinical data will be presented at ASCO.
The company anticipates completing the final analysis of OS data for the SOPHIA trial by the end of the third quarter.
Enrollment in Module B of the MAHOGANY study is ongoing in coordination with Zai Lab.
Revenue by Segment
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities as of March 31, 2021, as well as anticipated and potential collaboration payments, should enable it to fund its operations through 2023, assuming the Company’s programs and collaborations advance as currently contemplated.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...